Posted by Michael Wonder on 23 Jul 2025
GSK announces extension of US FDA an review period for Blenrep (belantamab mafodotin-blmf) in relapsed/refractory multiple myeloma
23 July 2025 - New PDUFA date scheduled for 23 October 2025.
GSK today announced the US FDA has extended the review period for the biologics license application for Blenrep combinations for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
